Gonadorelin

Generic Name: Gonadorelin

Brand Names: Lutrepulse

Drug Type: Small Molecule

Chemical Formula: C_₅₅H_₇₅N_₁₇O_₁₃

CAS Number: 33515-09-2

Unique Ingredient Identifier: 9O7312W37G

Background: Gonadorelin is another name for gonadotropin-releasing hormone (GnRH). It is a synthetic decapeptide prepared using solid phase peptide synthesis. GnRH is responsible for the release of follicle stimulating hormone and leutinizing hormone from the anterior pituitary.

Indication: For evaluating the functional capacity and response of the gonadotropes of the anterior pituitary also for evaluating residual gonadotropic function of the pituitary following removal of a pituitary tumor by surgery and/or irradiation.

Associated Therapies: Ovulation induction therapy

Clinical Trials

Value of Cabergoline and Low Dose Aspirin in Poor Responders Undergoing ICSI-ET With GnRH Agonist Flare-Up-Protocol

Phase 4

Conditions: Invitro Fertilization

Interventions: Drug: cabergoline
Drug: Aspirin
Drug: GnRH agonist

First Posted Date: 2017-08-28

Last Posted Date: 2017-08-28

Lead Sponsor: Cairo University

Target Recruit Count: 120

Registration Number: NCT03263299

Locations: 🇪🇬
Kasr Alainy medical school, Cairo, Egypt

Preventive Application of GnRH Antagonist on Early OHSS

Phase 4

Conditions: GnRH Antagonist
Pigment Epithelium Derived Factor
Ovarian Hyperstimulation Syndrome
Vascular Endothelial Growth Factor
Aspirin

Interventions: Drug: GnRH antagonist
Drug: aspirin

First Posted Date: 2017-06-15

Last Posted Date: 2017-06-15

Lead Sponsor: First Affiliated Hospital, Sun Yat-Sen University

Target Recruit Count: 175

Registration Number: NCT03188471

Locations: 🇨🇳
The First Affiliated Hospital of Sun Yatsen University, Guangzhou, Guangdong, China

Hormonal Mechanisms of Sleep Restriction - Axis Study

Phase 1

Active, not recruiting

Conditions: Sleep Restriction

Interventions: Drug: Gonadorelin
Drug: Ganirelix
Drug: Ketoconazole Pill
Drug: Dexamethasone Injection
Drug: Corticorelin
Drug: Hydrocortisone Injection
Drug: Dexamethasone
Drug: Placebo oral capsule
Drug: Cosyntropin Injectable Product
Drug: Saline Solution
Drug: Recombinant Human Luteinizing Hormone
Drug: Saline Solution for Injection

First Posted Date: 2017-05-08

Last Posted Date: 2024-04-23

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 80

Registration Number: NCT03142893

Locations: 🇺🇸
Los Angeles Biomedical Research Institute, Torrance, California, United States

Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)

Phase 2

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Drug: GnRH
Drug: Bicalutamide
Radiation: Salvage radiation
Drug: Abiraterone
Drug: Prednisone
Drug: Apalutamide

First Posted Date: 2017-05-05

Last Posted Date: 2024-05-14

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 345

Registration Number: NCT03141671

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States

and more 5 locations

Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer

Phase 4

Active, not recruiting

Conditions: Castration-Resistant Prostatic Cancer
Stage IV Prostate Cancer
Hormone-Refractory Prostate Cancer
Recurrent Prostate Carcinoma
Metastatic Prostate Carcinoma

Interventions: Biological: GnRH agonist/antagonist
Drug: Enzalutamide
Drug: Prednisone
Drug: Abiraterone Acetate

First Posted Date: 2017-01-11

Last Posted Date: 2025-04-27

Lead Sponsor: Northwestern University

Target Recruit Count: 100

Registration Number: NCT03016741

Locations: 🇺🇸
Tulane Cancer Center, New Orleans, Louisiana, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States

and more 2 locations

A Study to Assess the Safety and Efficacy of Enantone (Leuprorelin) in Central Precocious Puberty (CPP) Among Chinese Participants

Completed

Conditions: Central Precocious Puberty

Interventions: Drug: GnRH agonist
Drug: Enantone

First Posted Date: 2016-12-15

Last Posted Date: 2022-03-16

Lead Sponsor: Takeda

Target Recruit Count: 108

Registration Number: NCT02993926

Locations: 🇨🇳
The Children's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
🇨🇳
Childrens Hospital of Hunan province, Changsha, Hunan, China
🇨🇳
Jiangsu Province Hosptial, Nanjing, Jiangsu, China

and more 2 locations

Administration of Kisspeptin in Patients With Hyperprolactinemia

Phase 2

Completed

Conditions: Hypogonadism
Hyperprolactinemia

Interventions: Drug: Kisspeptin 112-121
Drug: GnRH

First Posted Date: 2016-11-06

Last Posted Date: 2024-10-01

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 36

Registration Number: NCT02956447

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Random-start Ovarian Stimulation in Egg-donors (ROSE)

Phase 4

Terminated

Conditions: Infertility

Interventions: Other: Random start ovarian stimulation
Drug: Gonadotrophins
Drug: GnRH antagonist
Drug: GnRH agonist

First Posted Date: 2016-07-04

Last Posted Date: 2019-08-19

Lead Sponsor: Instituto Bernabeu

Target Recruit Count: 15

Registration Number: NCT02821819

Locations: 🇪🇸
Instituto Bernabeu, Alicante, Spain

Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer

Phase 3

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Drug: approved GnRH agonist
Drug: Degarelix
Radiation: Radiotherapy

First Posted Date: 2016-06-15

Last Posted Date: 2024-11-05

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 885

Registration Number: NCT02799706

Locations: 🇧🇪
Hopitaux Universitaires Bordet-Erasme - Hopitaux Universitaires Bordet- Institut Jules Bordet, Brussels, Belgium
🇧🇪
Hopitaux Universitaires Bordet-Erasme - Hopital Universitaire Erasme, Brussels, Belgium
🇧🇪
Cliniques Universitaires Saint-Luc, Brussels, Belgium

and more 36 locations

Role of Aromatase Inhibitor to Enhance Ovulation in Poor Responder During Induction With Short Antagonist Protocol in Cases of ICSI

Phase 4

Completed

Conditions: Infertility Indicated for ICSI

Interventions: Drug: induction with aromataze inhibitor
Drug: HMG
Drug: GnRh a
Drug: HCG

First Posted Date: 2016-04-18

Last Posted Date: 2017-09-06

Lead Sponsor: Minia University

Target Recruit Count: 50

Registration Number: NCT02741154

Locations: 🇪🇬
Minia University, Minia, Egypt

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy